Subscribe to Search results

Armour,/Alpha, Travenol/Hyland, Miles/Cutter and Immuno all confirmed that their plasma came from plants that were licensed by the FDA and that the origins of their plasma were identifiable

Published on:

Professor Bloom stated that Profilate HT had the largest share of the commercial market.

Published on:

Hyland Therapeutics closed a plasma centre in Puerto Rico.

Published on:

Hyland Therapeutics closed the Mexico City plant (which used Mexican sourced plasma).

Published on:

Hyland Therapeutics closed that their sole plant in Lesotho.

Published on:

When AIDS cases first came to public attention in 1981 immigrants from Haiti were found to be at high risk of infection and hence unsuitable as donors.

Published on:

Dr Kingdon occupied various positions in Hyland Therapeutics.

Published on:

According to Dr Kingdon, the United States Federal Drug Administration (FDA) mandated source plasma as a licensed product. In order to obtain a licence for the production of source plasma every collection centre must be inspected annually by the FDA.

Published on:

According to Dr Kingdon, all plasma used for the production of concentrates in the United States had been obtained from donors in the United States.

Published on:

According to Dr Kingdon, it was unlikely that the industrial manufacturers in the US would have continued to use imported plasma in the manufacture of concentrates for any significant period as much of the imported plasma was infected with HBV.

Published on:

According to Dr Kingdon, a manufactured product might had a shelf life of two years.

Published on:

According to Dr Kingdon, the United Stated Federal Drug Administration's inspections of blood and plasma centres were important for changing practices in the plasma industry.

Published on:

The Draft Declaration of Trust Constituting Macfarlane Special Payments Trust excluded any further action in respect of HIV and hepatitis in Scotland as well as south of the border.

Published on:

Richard Henderson wrote to Ronald Powell to say that the Trust Deed and the undertaking not to take further legal action would have to be changed in respect of Scottish pursuers so that it no longer precluded any future action in respect of hepatitis.

Published on:

The Trust Deed was amended to set out, in a schedule, the undertakings to be given by Scottish litigants.

Published on:

The Macfarlane (Special Payments) (No.2) deed of trust was varied and the undertaking in the substituted schedule covering Scotland included, as per the agreement made in June 1991 in Scotland, HIV but not hepatitis.

Published on:

Scottish Home and Health Department officials became aware that the Scottish undertaking was different from the equivalent in England and Wales and sought to understand why.

Published on:

A scheme was drawn up for patients infected with HIV by blood and tissue transfer in Scotland. The reference to hepatitis in the proposed undertaking was deliberately removed.

Published on:

A minute seeking the approval of the NHS Chief Executive in Scotland recorded that "strong representations" had been received from the infected parties through their solicitors that because the settlement had been in respect of HIV, any undertaking to give effect to that settlement could not properly exclude hepatitis infections.

Published on:

A letter from Richard Henderson to J & A Hastie Solicitors referred to the reasons for excluding hepatitis infections from the undertaking.

Published on: